Cargando…

Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation

IMPORTANCE: Head-to-head randomized clinical trials showed greater efficacy of denosumab vs alendronate in improving bone mineral density. Although there is an association of changes in bone mineral density with reductions in fracture risk, the magnitude of the association is not well established. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pedersen, Alma B., Heide-Jørgensen, Uffe, Sørensen, Henrik T., Prieto-Alhambra, Daniel, Ehrenstein, Vera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481596/ https://www.ncbi.nlm.nih.gov/pubmed/31002319 http://dx.doi.org/10.1001/jamanetworkopen.2019.2416

Ejemplares similares

Comparison of the Effects of Denosumab and Alendronate on Cardiovascular and Renal Outcomes in Osteoporotic Patients
por: Hsu, Tsuen-Wei, et al.
Publicado: (2019)

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

Metformin initiation and renal impairment: a cohort study in Denmark and the UK
por: Christiansen, Christian Fynbo, et al.
Publicado: (2015)

The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study
por: Viggers, Rikke, et al.
Publicado: (2022)

What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia
por: Karnon, Jonathan, et al.
Publicado: (2016)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark
por: Corraini, Priscila, et al.
Publicado: (2017)

Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

Danish clinical quality databases – an important and untapped resource for clinical research
por: Sørensen, Henrik Toft, et al.
Publicado: (2016)

The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats
por: Hedvičáková, Věra, et al.
Publicado: (2023)

Effects of alendronate sodium combined with InterTan on osteoporotic femoral intertrochanteric fractures and fracture recurrence
por: Wang, Ke-Meng, et al.
Publicado: (2022)

Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures
por: Wang, Baohui, et al.
Publicado: (2022)

Prevalence and characteristics of patients with low levels of low-density lipoprotein cholesterol in northern Denmark: a descriptive study
por: Schmidt, Sigrun Alba Johannesdottir, et al.
Publicado: (2015)

Association of α1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark
por: Thomsen, Reimar W., et al.
Publicado: (2021)

Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study
por: Everts-Graber, Judith, et al.
Publicado: (2023)

Sampling strategies for selecting general population comparison cohorts
por: Heide-Jørgensen, Uffe, et al.
Publicado: (2018)

Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide
por: Tan, Juan, et al.
Publicado: (2019)

Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study
por: Abrahamsen, Bo, et al.
Publicado: (2016)

Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
por: Neuprez, A., et al.
Publicado: (2013)

Correction to: Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study
por: Everts-Graber, Judith, et al.
Publicado: (2023)

Cardiovascular Disease Among Women Who Gave Birth to an Infant With a Major Congenital Anomaly
por: Cohen, Eyal, et al.
Publicado: (2018)

Frozen shoulder and risk of cancer: a population-based cohort study
por: Pedersen, Alma B, et al.
Publicado: (2017)

The Role of Comorbidity in Mortality After Hip Fracture: A Nationwide Norwegian Study of 38,126 Women With Hip Fracture Matched to a General-Population Comparison Cohort
por: Lunde, Astrid, et al.
Publicado: (2019)

The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects
por: Chiu, Wei-Yih, et al.
Publicado: (2018)

Alendronate release from calcium phosphate cement for bone regeneration in osteoporotic conditions
por: van Houdt, Claire I. A., et al.
Publicado: (2018)

The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial
por: Iseri, Ken, et al.
Publicado: (2018)

Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial
por: Pawade, Tania A., et al.
Publicado: (2021)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still’s Disease—Denosumab Efficacy in Osteoporotic Still’s Disease Patients
por: Kumaki, Daiki, et al.
Publicado: (2018)

Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture
por: Iwamoto, Jun, et al.
Publicado: (2011)

Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway
por: Apalset, Ellen M., et al.
Publicado: (2020)

Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol
por: Bitto, A, et al.
Publicado: (2008)

The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy
por: Sewerynek, Ewa, et al.
Publicado: (2013)

Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study
por: Alishiri, Gholamhossein, et al.
Publicado: (2020)

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2020)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
por: Mori, Takahiro, et al.
Publicado: (2019)

Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women
por: Liu, Ting-Chun, et al.
Publicado: (2023)

Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan
por: Liu, Fang-Chun, et al.
Publicado: (2023)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Medical databases in studies of drug teratogenicity: methodological issues
por: Ehrenstein, Vera, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_3cfkrt6o6vg26o5sr297lud2f4